GLOBAL RHEUMATOID ARTHRITIS MARKET SET TO GROW TO $47BN BY 2024, SAYS VISIONGAIN.

Visiongain has launched a new pharma report:
Global Rheumatoid Arthritis Drugs Market Forecast 2019-2029: Biologics, Non-Biologics, NSAIDs, sDMARDs and Others.

Demand for RA drugs is on the rise, particularly in developing countries. The TNF inhibitors, which have dominated the market so successfully, are now coming to the end of their patents, opening the way for new biologics and biosimilars to compete for their share of the market. Following the launch of Xeljanz there are other oral DMARDs in development which could potentially undermine the role of the biologics. Changes in the next few years will be critical in determining the future treatment for RA.

For free sample pages on this report please click on:
https://www.visiongain.com/report/global-rheumatoid-arthritis-drugs-market-forecast-2019-2029/

The lead analyst of the report commented "one factor driving growth in this market is the discovery of new molecules that are involved in the disease process, hence, new strategies for treating the disease. Molecules such as TNFα, interleukin 6, interleukin 1, and janus kinase have all enabled the development of new treatments to target these molecules.
There are also several restraints on the RA drugs market which discourage the introduction of new drugs. One of these is the increasing pressure from governments to reduce the size of healthcare budgets and restrict the price of drugs. There are also drives to encourage physicians to prescribe generics and biosimilars rather than branded products, and to increase the percentage of patients who receive such products from year to year.”

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 549 9987.

Leading companies featured in the report include AbbVie, Amgen, AstraZeneca, BMS, Eli Lilly, Johnson & Johnson, Merck & Co, Novartis, Pfizer, Roche, Sanofi, UCB.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 549 9987.

For more Pharma reports please visit https://www.visiongain.com/industries/pharma/

Related reports:
• Global Asthma & COPD Therapies Market 2019-2029
(https://www.visiongain.com/report/global-asthma-copd-therapies-market-2019-2029/)
• Global Biosimilars and Follow-On Biologics Market 2019-2029
(https://www.visiongain.com/report/global-biosimilars-and-follow-on-biologics-market-2019-2029/)
• Biologics Market Trends and Forecasts 2018-2028
(https://www.visiongain.com/report/biologics-market-trends-and-forecasts-2018-2028/)
• Pharma Leader Series: Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market 2018
(https://www.visiongain.com/report/pharma-leader-series-top-50-pharmaceutical-contract-manufacturing-organisations-cmos-market-2018/)

Visiongain is one of the fastest-growing and most innovative independent business intelligence providers in Europe.
Based in London, UK, Visiongain publishes independent and insightful market reports across a wide range of industry verticals, including automotive, chemical, cyber, defence, energy, pharmaceutical, materials and many more sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. The company has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original business intelligence to depend upon.
https://www.visiongain.com/

Suite 143, Airport House Purley Way, Croydon CR0 0XZ

This release was published on openPR.